Nykode Therapeutics

We're #hiring a new Accountant in Oslo. Apply today or share this post with your network.

Nykode Therapeutics is proud to support Women in Life Science Norway (WiLD Norway), with the kick-off event happening this Thursday.   This event is a great opportunity to support gender balance and diversity in the life sciences sector—values that are key to driving innovation and growth. Looking forward to being part of this important initiative!   #WiLDNorway #WomenInLifeScienceNorway #WiLDCommunity #ClosetheGenderGap #ClosetheIndustryGap

Resharing this insightful podcast from RADFORSK with Nykode Therapeutics' Michael Engsig and Agnete Fredriksen, where they reflect on the challenging decision to discontinue the C-04 study, the formation of Nykode Tolerance to focus on autoimmune diseases, the partnerships with Genentech/Roche and Regeneron, and expected milestones going forward.   The podcast offers an in-depth view into the journey of Nykode, with both challenges and opportunities ahead. (Podcast and original post in Norwegian).

We are pleased to announce the presentation of a “Trial-in-Progress” (TiP) poster from our Phase 1/2a trial of VB10.16 C-03 in HNSCC at ESMO - European Society for Medical Oncology 2024.   The open-label, dose-finding trial evaluates the safety, immunogenicity, and anti-tumor activity of VB10.16 in combination with MSD’s PD-1 inhibitor KEYTRUDA® (pembrolizumab) in patients with HPV16-positive, PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) eligible for pembrolizumab monotherapy. The trial consists of two consecutive phases: a dose escalation phase (Phase 1) and a dose expansion phase (Phase 2a). It aims to determine the biological optimal dose of VB10.16 in combination with a fixed dose of pembrolizumab and elicited by doses of 3 mg, 6 mg, and 9 mg VB10.16.   Details for the Nykode Therapeutics’ presentation are as follows:   🔹 Title: A Phase 1/2a, Open-label, Dose-finding Trial to Evaluate Safety, Immunogenicity, and Anti-tumour Activity of VB10.16 in Combination with Pembrolizumab in Patients with Unresectable Recurrent or Metastatic HPV16-positive Head and Neck Squamous Cell Carcinoma (R/M HNSCC) 🕒 Time & Date: 12:00pm CET, September 14, 2024   The full poster will be available for viewing in the “R&D” section of Nykode's website: https://lnkd.in/eh4Nrx76.   #ESMO2024

🚀 Exciting News from Nykode Therapeutics! 🚀   We are thrilled to announce that the United States Patent and Trademark Office has issued a key patent for our fully individualized neoantigen-based vaccine, VB10.NEO. This patent, which is set to expire on January 5, 2037, marks a significant milestone in our mission to develop innovative cancer immunotherapies.   VB10.NEO is designed to target neoantigens—proteins generated by tumor-specific mutations—making it a promising treatment for locally advanced or metastatic solid tumors.   As Michael Engsig, CEO of Nykode, aptly stated, "The granting of this patent is a testament to the world-class innovation taking place in Nykode's labs. We remain dedicated to pushing the boundaries of what's possible in medicine, bringing hope to patients and their families around the globe."   We're proud to be at the forefront of cancer treatment innovation and look forward to continuing our work to make a difference in the lives of patients worldwide.   #CancerResearch #Immunotherapy #Innovation #VB10NEO #Patents #Biotech #HealthcareInnovation

🚀 Exciting news from Nykode!   We are thrilled to share that Jefferies, a globally recognized full-service investment bank, has initiated coverage on Nykode with a "Buy" rating and set a target price of NOK17.5. 🌟   This marks the second time a New York-based investment bank has initiated coverage on Nykode. 📈   A total of six banks are now covering Nykode, all recommending a "Buy" rating. This strong endorsement underscores the confidence and potential seen in our Nykode technology platform.   Stay tuned for more updates as we continue our journey. 💼🔬   #Nykode #Jefferies #BuyRating #Innovation #Biotech

We are delighted to share the latest podcast (in Norwegian) from Radforsk featuring our very own Michael Engsig and Agnete Fredriksen. They reflect on a busy six months of breakthroughs and exciting data, and look ahead to an equally promising year.

🌟 Nykode's Brian Weinert is participating in the Nature Conferences: Cancer Immunotherapy meeting in Boston, MA, from June 10th through June 12th. Our team is presenting research on our innovative cancer vaccine technology, which incorporates advanced mRNA-lipid nanoparticle (LNP) formats.   🔍 Our study, featured in poster presentation # 2-22 on June 11th, compares an APC-targeted neoantigen mRNA vaccine to an untargeted version across various mRNA-LNP doses. The APC-targeted vaccine consistently induced a stronger and broader immune response. In a mouse model of colorectal cancer, it also demonstrated superior tumor control and significantly better survival outcomes than the untargeted mRNA vaccine.   📊 For more details, please visit our poster on our website: https://lnkd.in/eh4Nrx76   #CancerResearch #Immunotherapy #Biotechnology #NatureConf #NatureCancer #NatureMedicine #NatImmunol   https://lnkd.in/eFMJeAJW

Nykode is pleased to announce an expansion of our collaboration with Merck (Merck & Co., Inc., Rahway, NJ, USA), focusing on the advancement of VB10.16 in combination with MSD’s KEYTRUDA® (pembrolizumab) in a Phase 2 trial for HPV16-positive high-risk cervical cancer. This partnership reflects our shared dedication to developing new immunotherapy treatments for cancer.    For more details on this collaboration, please read the full press release https://lnkd.in/eK8v6G-A.   We look forward to continuing our work with MSD to explore potential solutions for those affected by this disease.    #MSD #Oncology #ClinicalTrials #Immunotherapy #HealthcareInnovation

Thanks Catherine Shaffer for the great article!